EU approves Octava Pink test (Eventus Diagnostics) for detecting Breast Cancer
The EU have awarded CE mark approval to the Octava Pink breast cancer test, from Eventus Diagnostics. The test is one of a new class of rapid, accurate and cost-effective blood tests that measure cancer-specific autoantibodies to detect the presence or absence of Breast Cancer. The Octava confirmatory tests are designed to be used in conjunction with annual screening mammograms.
They have been validated by clinical studies conducted at multi-site cancer centers in Israel, Italy and the US that analyzed blood samples from over 800 women. Clinical data is expected to be published later this year, followed by a launch.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.